Novo Nordisk shares climbed more than 6% in early trading on Wednesday after its Wegovy pill outsold expectations and the company raised its full-year guidance. The Danish drugmaker now expects adjusted revenue and operating profit to range from a 2% decline to 2% growth at constant exchange rates, up from a previous forecast of minus 6% to flat. Third-quarter sales rose 4% to 79.2 billion Danish kroner, or $11.9 billion, ahead of the 73.6 billion kroner estimate. The Wegovy pill, launched this year, brought in 5.4 billion kroner against expectations of about 4.5 billion. Injectable Wegovy and Ozempic also beat forecasts. CFO Karsten Munk Knudsen will step down at the end of 2026 and be replaced by Galderma’s Luigi La Corte. Novo has fallen behind Eli Lilly this year, and its Copenhagen shares are still down about 17% in 2026.

Was this writing helpful?

Trust with CoinPedia:

CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:

All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:

Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.